MedPath

Summit Therapeutics Completes Enrollment in Phase 3 HARMONi Trial for Ivonescimab in Lung Cancer

• Summit Therapeutics completed patient enrollment for its Phase 3 HARMONi trial, evaluating ivonescimab plus chemotherapy for EGFR-mutated NSCLC. • The FDA granted ivonescimab Fast Track designation, potentially expediting the review process and availability of this novel biologic treatment. • H.C. Wainwright reaffirmed a Buy rating on Summit's stock with a $45 price target, citing ivonescimab's potential impact in NSCLC treatment. • Analysts project significant sales for ivonescimab, exceeding $6.5 billion by 2035, with potential to replace existing PD-1/L1 inhibitors.

Summit Therapeutics has announced the completion of patient enrollment in its Phase 3 HARMONi trial, a pivotal study evaluating the efficacy of ivonescimab in combination with chemotherapy for the treatment of a specific type of lung cancer. The trial focuses on patients with EGFR-mutated, locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor. The study is being conducted globally, with patient recruitment across North America, Europe, and China.

Fast Track Designation

The U.S. Food and Drug Administration (FDA) has granted ivonescimab Fast Track designation. This designation is designed to accelerate the review process for promising new therapies, allowing for more frequent communication with the FDA and a rolling review of the Biologics License Application (BLA). This could significantly speed up the potential approval and availability of ivonescimab if the HARMONi trial yields positive results.

Analyst Confidence

H.C. Wainwright has maintained a Buy rating on Summit Therapeutics' stock, with a price target of $45.00. This endorsement reflects confidence in ivonescimab's potential to address unmet needs in NSCLC treatment, particularly in areas where existing therapies like Merck & Co.'s KEYTRUDA may not be effective. The anticipated results from the HARMONi trial are considered a significant milestone for the company.

Market Potential

Analysts predict substantial market potential for ivonescimab, with projected sales exceeding $6.5 billion by 2035. Stifel raised its price target for Summit Therapeutics to $40, maintaining a Buy rating and highlighting ivonescimab's potential to replace existing PD-1/L1 inhibitors and significantly expand the addressable market. This optimistic outlook is based on promising Phase 2 clinical trial data presented at the European Society of Medical Oncology annual meeting.

InvestingPro Insights

Summit Therapeutics' stock has demonstrated remarkable performance, with a 933.89% price total return over the past year. InvestingPro data indicates that three analysts have revised their earnings upwards for the upcoming period, suggesting growing confidence in Summit's potential. The company's liquid assets exceed short-term obligations, indicating a solid financial position to support its ongoing clinical trials.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ultragenyx Initiates Phase 3 Aspire Study of GTX-102 for Angelman Syndrome

Ultragenyx has commenced the Phase 3 Aspire study to evaluate GTX-102, an experimental treatment for Angelman syndrome, in children aged 4 to 17.
The Aspire study is a randomized, sham-controlled trial with a 48-week primary efficacy analysis period, measuring cognitive improvement via the Bayley-4 cognitive raw score.

Cognition Therapeutics Price Target Increased by H.C. Wainwright

H.C. Wainwright has raised its price target for Cognition Therapeutics from $5 to $6, maintaining a Buy rating, following positive Phase 2 SHIMMER trial results for CT1812 in treating dementia with Lewy bodies.

Assertio Therapeutics Receives Buy Rating Following Positive Clinical Trial Results

H.C. Wainwright reaffirms a Buy rating for Assertio Therapeutics, citing promising clinical trial outcomes for ROLVEDON in early-stage breast cancer treatment, with a price target of $4.00.

Scholar Rock's Stock Target Increased Following SMA Study Results

H.C. Wainwright has raised Scholar Rock's stock price target to $50 from $40, maintaining a Buy rating, after Biohaven's Phase 3 RESILIENT study for SMA treatment did not meet its primary outcome. Scholar Rock's apitegromab is seen as having fewer market challenges, with increased global penetration assumptions leading to a revised peak sales projection of $1.12 billion by 2034.

Humacyte's ATEV Shows Promise in Clinical Trials, Driving Optimistic Market Outlook

Humacyte's Acellular Tissue Engineered Vessel (ATEV) demonstrates significant advantages in clinical settings, including infection resistance and durability, compared to traditional prosthetic grafts.
Clinical trials, such as the V007 Phase 3 study and real-world data from Ukraine, highlight ATEV's efficacy with higher patency rates and fewer complications in vascular trauma repair.

Tempest Therapeutics Advances Liver Cancer Therapy with Roche Partnership

Tempest Therapeutics partners with Roche for a Phase 3 trial of amezalpat in first-line Hepatocellular Carcinoma (1L HCC).
The FDA agreed to the Phase 3 study plan, potentially reducing the timeline to primary analysis by eight months.

Summit Therapeutics' Lung Cancer Drug Ivonescimab Receives FDA Fast Track Designation

Summit Therapeutics' stock experienced a surge following the FDA's Fast Track designation for its lung cancer drug, ivonescimab, indicating accelerated review potential.
The company has completed enrollment for a Phase 3 trial of ivonescimab, involving patients across North America, Europe, and China, marking its first global study.

Acasti Pharma's GTX-104 Trial for aSAH Completes Enrollment Early, Eyes 2026 Launch

Acasti Pharma's STRIVE-ON trial, evaluating GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH), has completed enrollment ahead of schedule with approximately 100 participants.
Top-line data from the pivotal safety trial is expected by February, potentially leading to a New Drug Application (NDA) filing by June 2025.

ORIC Pharmaceuticals Maintains Buy Rating Amidst Competitive Landscape

H.C. Wainwright reaffirms its Buy rating and $21 price target for ORIC Pharmaceuticals, following a review of competitor Ipsen's trial results at the ESMO 2024 conference. Despite Ipsen's positive outcomes, ORIC's potential in prostate cancer treatments and its financial stability keep investor confidence high.

Kymera Therapeutics Shares Price Target Rises on Positive Development

H.C. Wainwright has raised Kymera Therapeutics' stock price target to $60, citing Sanofi's decision to expand Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis. This move is seen as a positive development for Kymera, with the potential success of its KT-474 program influencing the decision.

Reference News

[1]
H.C. Wainwright keeps buy rating on Summit Therapeutics stock, highlighting Fast Track designation
investing.com · Oct 4, 2024

H.C. Wainwright maintains Buy rating and $45 price target for Summit Therapeutics, following completion of Phase 3 HARMO...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy